June 5, 2018
CannTrust™ Announces Closing of $100,395,000 Bought Deal
VAUGHAN, ON, June 5, 2018 /CNW/ – CannTrust Holdings Inc. (TSX: TRST) (“CannTrust” or the “Company“), a licensed producer of medical cannabis under the Health Canada Access to Cannabis for Medical Purposes Regulation (“ACMPR“) program, today announced that it has closed its previously announced short form prospectus offering, on a bought deal basis, including the full exercise of the over-allotment option. A total of 11,155,000 units of the Company (“Units“) were sold at a price of $9.00 per Unit for aggregate gross proceeds of $100,395,000 (the “Offering“).
Read the full press release here.
LATEST NEWS
See All News
Canada
in
Canada in Science - November 9, 2018
Canada in Science - November 9, 2018
America's
Midwestern
America's Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub
America's Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub
Canada
in
Canada in Science - September 7, 2018
Canada in Science - September 7, 2018
Q2
2018
Q2 2018 Share Price Performance
Q2 2018 Share Price Performance
Canada
in
Canada in Science - August 3, 2018
Canada in Science - August 3, 2018
Canada
in
Canada in Science - July 6, 2018
Canada in Science - July 6, 2018
Greenbrook
TMS
Greenbrook TMS Announces Closing of Private Placement Totaling USD $20,000,000
Greenbrook TMS Announces Closing of Private Placement Totaling USD $20,000,000
Canada
in
Canada in Science - June 7, 2018
Canada in Science - June 7, 2018
CannTrust™
Announces
CannTrust™ Announces Closing of $100,395,000 Bought Deal
CannTrust™ Announces Closing of $100,395,000 Bought Deal
Bloom
Burton
Bloom Burton & Co. Welcomes Michael J. Brown, CFA® as Portfolio Manager and Chief Executive Officer of its Asset Management Affiliate, Bloom Burton Investment Group.
Bloom Burton & Co. Welcomes Michael J. Brown, CFA® as Portfolio Manager and Chief Executive Officer of its Asset Management Affiliate, Bloom Burton Investment Group.
Q1
2018
Q1 2018 Share Price Performance
Q1 2018 Share Price Performance
From
Motor
From Motor City to Health Innovation City? Detroit's Unexpected Comeback
From Motor City to Health Innovation City? Detroit's Unexpected Comeback
Kneat
Announces
Kneat Announces Closing of $6.185 Million Brokered Private Placement
Kneat Announces Closing of $6.185 Million Brokered Private Placement
Canada
in
Canada in Science - April 6, 2018
Canada in Science - April 6, 2018
Sunniva
Inc.
Sunniva Inc. Closes $27.8 Million Bought Deal Public Offering
Sunniva Inc. Closes $27.8 Million Bought Deal Public Offering
Immunovaccine
Announces
Immunovaccine Announces Closing of CAD$14,375,000 Bought Deal Offering with Over-Allotment Option Exercised in Full
Immunovaccine Announces Closing of CAD$14,375,000 Bought Deal Offering with Over-Allotment Option Exercised in Full
Canada
in
Canada in Science - March 2, 2018
Canada in Science - March 2, 2018
Big
Pharma's
Big Pharma's Drug War: Innovative vs. Generic and Biosimilar Drugs
Big Pharma's Drug War: Innovative vs. Generic and Biosimilar Drugs
Bloom
Burton
Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala
Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala
Canada
in
Canada in Science - Feb 2, 2018
Canada in Science - Feb 2, 2018
Plasma
for
Plasma for Profit: The Changing Landscape of Blood Donation
Plasma for Profit: The Changing Landscape of Blood Donation
Q4
&
Q4 & Annual 2017 Share Price Performance - Part 3
Q4 & Annual 2017 Share Price Performance - Part 3
Q4
&
Q4 & Annual 2017 Share Price Performance - Part 2
Q4 & Annual 2017 Share Price Performance - Part 2
ESSA
Completes
ESSA Completes US$26 Million Equity Offering
ESSA Completes US$26 Million Equity Offering
Paul
Lammers,
Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer
Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer
Q4
Share
Q4 Share Price Performance in 2017 - Part 1
Q4 Share Price Performance in 2017 - Part 1
BELLUS
Health
BELLUS Health Closes $20M Common Share Financing
BELLUS Health Closes $20M Common Share Financing
Canada
in
Canada in Science - December 1, 2017
Canada in Science - December 1, 2017
Avivagen
Announces
Avivagen Announces Closing of Private Placement Totaling $4,000,000
Avivagen Announces Closing of Private Placement Totaling $4,000,000
CannTrust™
Announces
CannTrust™ Announces Closing of $20,000,000 Bought Deal
CannTrust™ Announces Closing of $20,000,000 Bought Deal
The
Emergence
The Emergence of the HIV/AIDS Epidemic and How it Affected the Human Plasma Industry
The Emergence of the HIV/AIDS Epidemic and How it Affected the Human Plasma Industry
Q3
Share
Q3 Share Price Performance in 2017 - Part 3
Q3 Share Price Performance in 2017 - Part 3
Q3
Share
Q3 Share Price Performance in 2017 - Part 2
Q3 Share Price Performance in 2017 - Part 2
Q3
Share
Q3 Share Price Performance in 2017 - Part 1
Q3 Share Price Performance in 2017 - Part 1
Canada
in
Canada in Science - November 3, 2017
Canada in Science - November 3, 2017
Acquisitions
in
Acquisitions in the Life Sciences Start-Up Space: A Principal-Agent Problem in the Making
Acquisitions in the Life Sciences Start-Up Space: A Principal-Agent Problem in the Making
Appili
Therapeutics
Appili Therapeutics Receives FDA and Health Canada Clearance to Begin Clinical Trials on ATI-1501
Appili Therapeutics Receives FDA and Health Canada Clearance to Begin Clinical Trials on ATI-1501
